Tirzepatide: What SURMOUNT-X Proved About Sustained Weight Loss in 2026

Three years. That is how long many patients using weight loss medication fear the rebound effect will last. Anyone who has tried knows the feeling. The weight comes back, motivation drops, and it feels like the body conspired against you. The SURMOUNT-X study came to change that conversation.

Tirzepatide, the active ingredient in medications like Mounjaro, showed results that go beyond the number on the scale. Study participants maintained, on average, a 22.5% reduction in body weight for more than three years. This is not quick loss. It is real sustainment.

What SURMOUNT-X Was

SURMOUNT-X was a phase 3 clinical trial that followed patients with obesity or overweight with at least one weight-related comorbidity. The study design was robust: it lasted 72 weeks of initial treatment, followed by a 104-week maintenance period. In total, three years of follow-up.

Participants received weekly tirzepatide doses, with gradual titration up to the maximum tolerated dose. There was no one-size-fits-all protocol. Medication was adjusted based on individual response.

The primary endpoint was the percentage change in body weight from baseline. Secondary endpoints included changes in metabolic parameters, blood pressure, lipid profile, and glycemic control.

The Numbers That Stood Out

The average 22.5% reduction exceeded what had been seen in previous studies with other medications in the same class. For a practical sense of what that means, a 100-kilogram person lost and maintained an average of 22.5 kilograms throughout the follow-up period.

Almost 70% of participants achieved at least 15% weight loss from their starting weight. And nearly 40% reached a reduction above 25%. These are numbers that genuinely change lives, not just the number on the scale display.

What impressed researchers was the ability to maintain results. Less than 10% of participants who reached their target weight showed significant regain during the maintenance period.

How Tirzepatide Works in the Body

Tirzepatide works by mimicking two intestinal hormones: GLP-1 and GIP. These hormones are part of the incretin axis, which regulates satiety and blood sugar control.

When you eat, your intestine releases these hormones. Your brain interprets that as a signal that it is time to stop. At the same time, your stomach empties more slowly, prolonging the feeling of fullness.

What sets tirzepatide apart from earlier medications is precisely this dual action. By acting on both receptors, the effect on satiety and appetite control is more intense. Studies show that patients report less hunger, fewer obsessive thoughts about food, and more ease in maintaining consistent food choices over time.

The Role of Long-Term Follow-Up

A detail that does not always appear in articles about the topic: behavioral support was part of the protocol. Participants had access to guidance on nutrition and physical activity, adjusted over time.

This matters because no medication works in isolation. Medication opens a window of opportunity. It reduces hunger, improves appetite control, and makes adherence easier. But building new habits needs to happen alongside it.

Tracking apps can fill that space. Ozempro, for example, lets you log meals, monitor symptoms, and track how your treatment is progressing. Having that data organized makes conversations with your doctor more productive and helps identify patterns that would otherwise go unnoticed. If you are interested in understanding how this tool can be useful in your case, clicking here takes you to a quick quiz designed to guide you.

What This Means in Practice

For those who have tried everything and nothing stuck, the three-year sustainment data is a turning point. It means there is now a path where loss does not have to be followed by inevitable regain.

Of course, every body responds differently. Genetics, metabolism, pre-existing health conditions, use of other medications. All of these affect the outcome. What SURMOUNT-X shows is that, as a group, patients who used tirzepatide with proper follow-up were able to maintain their weight reduction over a significant period.

Another practical point: the medication was not associated with serious long-term side effects in the study. The most common ones were gastrointestinal, such as nausea and diarrhea, especially during the titration phase. These effects tend to decrease over time.

Who Can Benefit

The patient profile studied included people with BMI starting at 30, or 27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.

Medical evaluation is indispensable before starting any medication in this class. Only a healthcare professional can assess contraindications, drug interactions, and determine whether the potential benefit justifies treatment in your specific case.

The cost of treatment is also a real factor. Medications in this class are still expensive in Brazil, and access is limited for those without health insurance that covers them. This is a reality that needs to be discussed openly with your doctor.

What to Expect Going Forward

SURMOUNT-X data opens the door for a more honest conversation about obesity treatment. For decades, medical discourse blamed the patient for lack of willpower. Science is showing the problem is more complex, and that adequate pharmacological intervention makes a real difference.

Studies continue to be conducted. In the long run, the question that remains is about the ideal duration of treatment. Does it need to be forever? Can breaks be taken? How does reintroduction work if the weight comes back? Answers are still being built.

The important thing is knowing that there is more evidence than ever that sustained weight loss is possible. Not with magic, not with secret formulas, but with science, follow-up, and the right support tools. The first step remains seeking quality information and talking to a trusted healthcare professional.